PODD
$227.10-1.53 (-0.67%)
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally.
Recent News
Is Insulet Stock Underperforming the Dow?
Insulet has underperformed the Dow recently, yet analysts remain highly optimistic about the stock’s prospects.
Should You Continue to Hold Insulet Stock in Your Portfolio?
PODD's Omnipod 5 momentum and strong growth outlook highlight upside, but macro pressures and rising competition could challenge its near-term performance.
Insulet (PODD) Down 8.2% Since Last Earnings Report: Can It Rebound?
Insulet (PODD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
1 Healthcare Stock with Exciting Potential and 2 We Avoid
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 3.6% gain over the past six months, beating the S&P 500 by 2.3 percentage points.
This Biotech Stock Up Nearly 100% in a Year Has Drawn a New $20 Million Share Investment
EyePoint develops sustained-release treatments for retinal diseases, leveraging proprietary technology and strategic industry partnerships.